statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO, July...

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant...

Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes

Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes Regulus Therapeutics Announces Expected Addition to the Russell 3000 and Russell 2000 Indexes PR Newswire...

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire...

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire SAN DIEGO, May 9...

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Regulus...

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for...

StockNews.com Initiates Coverage on Regulus Therapeutics (NASDAQ:RGLS)

StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) in a research note issued on Sunday. The brokerage set a "hold" rating on the biopharmaceutical...

Short Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Grows By 9,244.3%

Regulus Therapeutics Inc. (NASDAQ:RGLS  Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,130,000...

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $7.50 Average Target Price from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS  Get Free Report) have been given a consensus rating of Moderate Buy by the five brokerages that are currently covering the...

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Volume	1.51M
52-Wk High	$3.79
52-Wk Low	$1.08

RGLS Regulus Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals